OncoMatch/Clinical Trials/NCT06493760
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Is NCT06493760 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for metastatic colorectal cancer.
Treatment: SSGJ-707 · Bevacizumab · Oxaliplatin · Capecitabine · Calcium Folinate · 5-fluorouracil — This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06493760 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages